Upgrading the Gleason score in extended prostate biopsy: implications for treatment choice.
about
The accuracy of pathological data for the prediction of insignificant prostate cancer.Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study.Discrimination of prostate carcinoma from benign prostate tissue fragments in vitro by estimating the gross biochemical alterations through Raman spectroscopy.Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary gradesImportance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens.Change in the risk stratification of prostate cancer after Slide Review by a uropathologist: the experience of a reference center for the treatment of prostate cancer.Controlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate Cancer.Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.3D versus 2D Systematic Transrectal Ultrasound-Guided Prostate Biopsy: Higher Cancer Detection Rate in Clinical Practice.PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.Real-time registration of 3D to 2D ultrasound images for image-guided prostate biopsy.Evaluating the utility of intraprocedural 3D TRUS image information in guiding registration for displacement compensation during prostate biopsy.2D-3D rigid registration to compensate for prostate motion during 3D TRUS-guided biopsy.Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
P2860
Q30585256-00BCBC01-41B1-4C59-B899-C6242B6E16C4Q34664915-08A8BFDB-7C1F-464C-844D-ED0ED7C9AF2EQ35118105-80F9413F-FA2D-42EC-97E4-1F795C644980Q36318643-A7D15A4F-9965-4FC1-8148-A3BE5A74E9CCQ36906894-B7857190-B087-44D3-AD92-6EE51B926CBEQ38253942-95791E1C-B4B3-40C2-9DB0-BB4CAE537193Q38911575-28EA6996-7C80-4F9C-904C-35890B64B9B3Q40144303-688995C5-0030-4880-B2D9-BAA8947F8594Q40463189-91D4D0A4-82CD-407A-AE83-29FE62BF6CD9Q42836179-9E4CF54C-3643-4D2B-AC4C-016A03F27F8CQ46826597-4D5F8FB1-17E2-45EB-81AD-6E445DC16F8DQ47781877-781CB09B-4DDE-43C9-BBDA-D802E62EA590Q51062171-5ACDF258-8E17-48D2-97EB-52D60ADA592EQ51263248-AD1A1158-3BB8-402D-B2C7-E2F1EF083024Q54311845-AF05811B-776F-47FB-8095-0DC67CCC5DBF
P2860
Upgrading the Gleason score in extended prostate biopsy: implications for treatment choice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Upgrading the Gleason score in ...... ications for treatment choice.
@en
Upgrading the Gleason score in ...... ications for treatment choice.
@nl
type
label
Upgrading the Gleason score in ...... ications for treatment choice.
@en
Upgrading the Gleason score in ...... ications for treatment choice.
@nl
prefLabel
Upgrading the Gleason score in ...... ications for treatment choice.
@en
Upgrading the Gleason score in ...... ications for treatment choice.
@nl
P2093
P1476
Upgrading the Gleason score in ...... ications for treatment choice.
@en
P2093
Alberto A Antunes
Katia Ramos Moreira Leite
Luiz H A Camara-Lopes
Miguel Srougi
P304
P356
10.1016/J.IJROBP.2008.04.039
P407
P577
2008-09-05T00:00:00Z